EXTON, Pa.--(BUSINESS WIRE)--Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), today announced that the US Patent and Trademark Office (USPTO) issued US patent number 7,795,019 covering its novel Breast Cancer Resistance Protein (BCRP) knockdown cell line within the company’s CellPort Technologies® brand. Absorption Systems’ proprietary cell lines allow pharmaceutical and biotechnology companies to definitively predict clinical drug-drug interactions (DDIs) involving drug transporters.
